Dyadic Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 10, 2023 16:00 ET
|
Dyadic International, Inc.
New research collaboration with a Top 5 pharmaceutical company to develop C1 expressed vaccine antigen for human healthExpanded licensing agreement with Rubic One Health (“Rubic”) to develop,...
Endominance Launches Exciting New Microbiome, Anxiety, and Cognitive Orientation Study
April 14, 2022 17:00 ET
|
Endominance, Inc.
IRVINE, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Endominance, Inc., a leading cognitive assessment and data collection firm headquartered in Virginia, today announced the launch of a...
Dyadic Introduces Novel Method to Produce Synthetic Cannabinoids and Precursors Utilizing C1 Cell Line Production Platform and Patent Pending Process
January 20, 2022 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...
PROCESSA PHARMACEUTICALS PROVIDES A STUDY UPDATE FOR ITS ON-GOING PHASE 2 SAFETY AND TOLERABILITY CLINICAL TRIAL OF PCS-499
July 15, 2019 09:30 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, July 15, 2019 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of...
PROCESSA PHARMACEUTICALS ANNOUNCES PRESENTATION OF PCS499 DATA AT THE ANNUAL MEETING OF AMERICAN ACADEMY OF DERMATOLOGY
January 09, 2019 09:00 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Jan. 09, 2019 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of...